ERIC 2018 | Bispecific antibody response boosting with ibrutinib for CLL
Adrian Wiestner
• 25 Oct 2018
Bispecific antibodies rely upon the T-cells already present in a patient, opposed to CAR T-cells where these cells are taken and altered prior to therapy. Adrian Wiestner, MD, PhD, of the National Institute of Health, Bethesda, MD, gives us his insight here on the use of bispecific antibodies for the treatment of chronic lymphocytic leukemia (CLL). Dr Wiestner highlights the combination of ibrutinib with these antibodies, which has been shown to improve response rates. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
